Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Liabilities and Shareholders Equity (2022 - 2025)

Historic Liabilities and Shareholders Equity for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $327.2 million.

  • Zentalis Pharmaceuticals' Liabilities and Shareholders Equity fell 2738.44% to $327.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year decrease of 2720.89%. This contributed to the annual value of $430.3 million for FY2024, which is 2199.63% down from last year.
  • Latest data reveals that Zentalis Pharmaceuticals reported Liabilities and Shareholders Equity of $327.2 million as of Q3 2025, which was down 2738.44% from $351.7 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Liabilities and Shareholders Equity peaked at $621.4 million during Q2 2023, and registered a low of $327.2 million during Q3 2025.
  • Its 4-year average for Liabilities and Shareholders Equity is $485.6 million, with a median of $491.7 million in 2024.
  • In the last 5 years, Zentalis Pharmaceuticals' Liabilities and Shareholders Equity soared by 2062.36% in 2023 and then tumbled by 3111.47% in 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $539.3 million in 2022, then rose by 2.3% to $551.7 million in 2023, then dropped by 22.0% to $430.3 million in 2024, then dropped by 23.95% to $327.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $327.2 million in Q3 2025, compared to $351.7 million in Q2 2025 and $384.0 million in Q1 2025.